Previous close | 0.4200 |
Open | 0.3700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.3700 - 0.3700 |
52-week range | 0.3700 - 0.4200 |
Volume | |
Avg. volume | 177 |
Market cap | 26.986M |
Beta (5Y monthly) | 1.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS & BOSTON, May 21, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the availability of preparatory documents for the Combined General Meeting of June 6, 2024, to be held at 11:00 a.m. at the Company's head office at 9 rue d'Enghien, 75010 - Paris.
PARIS, May 17, 2024--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
PARIS & BOSTON, May 06, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the presentation of 9 abstracts supporting Cellvizio® at the Digestive Disease Week® (DDW) Conference, being held on May 18-21, 2024 in Washington, DC. These abstracts focus on artificial intelligence, pancreatic cystic lesions and pancreatic cancer, food intolerance an